Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vincristine + l-asparaginase + doxorubicin + cyclophosphamide + cytarabine + dexamethasone + intrathecal methotrexate
- Development stage
- Unknown
- Lead developer
- Hee Young Ju
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Intrathecal, Intramuscular, Oral
01
Overview
This multi-agent chemotherapy regimen is a combination of seven distinct pharmacological agents used in the treatment of pediatric acute lymphoblastic leukemia (ALL). It is specifically employed during the 'Delayed Intensification' (DI) phase of risk-stratified treatment protocols, such as those investigated by Hee Young Ju. The regimen consists of vincristine (a microtubule inhibitor), L-asparaginase (an enzyme that depletes serum asparagine), doxorubicin (an anthracycline that inhibits topoisomerase II and intercalates DNA), cyclophosphamide (a nitrogen mustard alkylating agent), cytarabine (a pyrimidine analog DNA synthesis inhibitor), dexamethasone (a potent synthetic glucocorticoid), and methotrexate (a folate antagonist administered intrathecally for central nervous system prophylaxis). This combination is designed to maximize leukemic cell kill through multiple non-overlapping mechanisms of action while preventing CNS relapse.
- Other names
- vincristine + l-asparaginase + doxorubicin + cyclophosphamide + cytarabine + dexamethasone + intrathecal methotrexate-Hee Young Ju-acute lymphoblastic leukemiaDelayed Intensification regimenDI chemotherapy
02
Targets
DNA polymerase familyTUBB (Tubulin (alpha and beta subunits))TOP2A (DNA topoisomerase II)DHFR (Dihydrofolate reductase)GR (Glucocorticoid receptor)DNA
Beyond the preview
Go deeper on vincristine + l-asparaginase + doxorubicin + cyclophosphamide + cytarabine + dexamethasone + intrathecal methotrexate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vincristine + l-asparaginase + doxorubicin + cyclophosphamide + cytarabine + dexamethasone + intrathecal methotrexate.